Update on Drug-Induced Pneumonitis in Lung Cancer

Abstract

Drug-induced pneumonitis is a significant and potentially life-threatening complication associated with multiple lung cancer therapies. As novel therapies are introduced and incorporated into updated treatment algorithms, it is crucial to anticipate, recognize, and manage these events readily and comprehensively. As experience with these agents accumulates in real-world settings, so too does our appreciation for patient risk factors, the need for personalized monitoring strategies, the heterogeneity of both clinical and radiographic presentations, and the persistent importance of a systematic approach to diagnosis and management. Novel therapies are responsible for significant improvements in lung cancer survival, but enthusiasm for this progress must be tempered by mitigation and management of inherent risks to avoid undue morbidity and mortality for our patients. Challenging clinical scenarios such as steroid-refractory pneumonitis highlight the importance of thorough evaluation, confident attribution, and aggressive early management. Future elucidation of the pathophysiology of these reactions will hopefully refine future diagnostic and therapeutic options. A collaborative, multidisciplinary approach is essential to optimize patient safety and outcomes in lung cancer care. In this study, we describe approaches to pretreatment assessment, evaluation of suspected pneumonitis, and management of pneumonitis on a drug-specific basis. We emphasize emerging data and drug classes, while also highlighting remaining areas of uncertainty.

Keywords

drug-induced pneumonitis - interstitial lung disease - lung cancer - immune checkpoint inhibitor - antibody drug conjugate - molecularly targeted agents

Note

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Publikationsverlauf

Accepted Manuscript online:
28. Juli 2025

Artikel online veröffentlicht:
29. August 2025

• References

• 1 Lin MX, Zang D, Liu CG, Han X, Chen J. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management. Front Immunol 2024; 15: 1266850
• 2 Powell CA, Modi S, Iwata H. et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 2022; 7 (04) 100554
• 3 Hanibuchi M, Ogino H, Sato S, Nishioka Y. Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : a literature review and future perspectives. J Med Invest 2024; 71 (1.2): 9-22
• 4 Tamiya A, Naito T, Miura S. et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 2012; 32 (03) 1103-1106
• 5 Tomii K, Kato T, Takahashi M. et al. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). Jpn J Clin Oncol 2017; 47 (04) 350-356
• 6 Suh CH, Park HS, Kim KW, Pyo J, Hatabu H, Nishino M. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer 2018; 123: 60-69
• 7 Gemma A, Kusumoto M, Kurihara Y. et al. Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib. J Thorac Oncol 2019; 14 (04) 672-682
• 8 Onishi H, Kuriyama K, Yamaguchi M. et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003; 40 (01) 79-84
• 9 Barlési F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004; 18 (01) 85-91
• 10 Suresh K, Voong KR, Shankar B. et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 2018; 13 (12) 1930-1939
• 11 Lu S, Kato T, Dong X. et al; LAURA Trial Investigators. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 2024; 391 (07) 585-597
• 12 Zhu Z, Shen G, Li J. et al. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2023; 184: 103960
• 13 Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol 2018; 4 (08) 1112-1115
• 14 Schoenfeld AJ, Arbour KC, Rizvi H. et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 2019; 30 (05) 839-844
• 15 Otsubo K, Okamoto I, Hamada N, Nakanishi Y. Anticancer drug treatment for advanced lung cancer with interstitial lung disease. Respir Investig 2018; 56 (04) 307-311
• 16 Beasley MB. Interstitial lung abnormalities. Surg Pathol Clin 2024; 17 (02) 215-225
• 17 Drakopanagiotakis F, Krauss E, Michailidou I. et al. Lung cancer and interstitial lung diseases. Cancers (Basel) 2024; 16 (16) 2837
• 18 Shibaki R, Ozawa Y, Noguchi S. et al. Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib. Cancer Med 2022; 11 (20) 3743-3750
• 19 Yamaguchi O, Kaira K, Shinomiya S. et al. Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab. Thorac Cancer 2021; 12 (03) 304-313
• 20 Otsubo K, Kishimoto J, Ando M. et al. Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. Eur Respir J 2022; 60 (06) 2200380
• 21 Chu X, Zhao J, Zhou J. et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer 2020; 150: 76-82
• 22 Wang H, Zhou F, Zhao C. et al. Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy. Front Immunol 2022; 13: 840313
• 23 Tanahashi H, Yamaguchi K, Kurose K. et al. Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis. Respirology 2023; 28 (04) 380-388
• 24 Correale P, Saladino RE, Giannarelli D. et al. HLA expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis. Cells 2020; 9 (09) 1964
• 25 Xin Z, You L, Na F. et al. Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors. Eur J Cancer 2023; 184: 124-136
• 26 Du Y, Zhang S, Jia X. et al. Radiomics biomarkers to predict checkpoint inhibitor pneumonitis in non-small cell lung cancer. Acad Radiol 2025; 32 (03) 1685-1695
• 27 Shu Y, Xu W, Su R. et al. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis. Front Immunol 2023; 14: 1251645
• 28 Gaga M, Powell CA, Schraufnagel DE. et al; ATS/ERS Task Force on the Role of the Pulmonologist in the Management of Lung Cancer. An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med 2013; 188 (04) 503-507
• 29 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer V1.2025. National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 1, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org
• 30 Henning JW, Brezden-Masley C, Gelmon K. et al. Managing the risk of lung toxicity with trastuzumab deruxtecan (T-DXd): a Canadian perspective. Curr Oncol 2023; 30 (09) 8019-8038
• 31 Upperton S, Beirne P, Bhartia B. et al. Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire lung screening trial. BMJ Open Respir Res 2023; 10 (01) e001490
• 32 Franzen D, Schad K, Kowalski B. et al. Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study. Cancer Immunol Immunother 2018; 67 (01) 127-134
• 33 Swain SM, Nishino M, Lancaster LH. et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022; 106: 102378
• 34 Müller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004; 91 (Suppl. 02) S24-S30
• 35 Limper AH. Drug-Induced Pulmonary Disease. In: Broaddus VC. ed. Murray & Nadel's Textbook of Respiratory Medicine. 7 ed. Elsevier; 2022. : Chapter 99.
• 36 Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004; 91 (Suppl. 02) S18-S23
• 37 Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open 2022; 7 (04) 100553
• 38 Bledsoe TJ, Nath SK, Decker RH. Radiation pneumonitis. Clin Chest Med 2017; 38 (02) 201-208
• 39 Salem PP, Chami P, Daou R. et al. Proton radiation therapy: a systematic review of treatment-related side effects and toxicities. Int J Mol Sci 2024; 25 (20) 10969
• 40 Zhao J, Yorke ED, Li L. et al. Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies. Int J Radiat Oncol Biol Phys 2016; 95 (05) 1357-1366
• 41 Nishino M. Imaging of oncologic treatment-related pneumonitis: a focused review on emerging issues of immune checkpoint inhibitor pneumonitis, from the AJR special series on inflammation. AJR Am J Roentgenol 2022; 218 (01) 19-27
• 42 Forschner A, Zips D, Schraml C. et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 2014; 24 (05) 512-516
• 43 Champiat S, Lambotte O, Barreau E. et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27 (04) 559-574
• 44 Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004; 25 (01) 53-64
• 45 Haanen J, Obeid M, Spain L. et al; ESMO Guidelines Committee. Electronic address: [e-mail]. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33 (12) 1217-1238
• 46 Strippoli S, Fucci L, Negri A. et al. Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma. J Transl Med 2020; 18 (01) 473
• 47 Lin X, Deng H, Yang Y. et al. Peripheral blood biomarkers for early diagnosis, severity, and prognosis of checkpoint inhibitor-related pneumonitis in patients with lung cancer. Front Oncol 2021; 11: 698832
• 48 Colen RR, Fujii T, Bilen MA. et al. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs 2018; 36 (04) 601-607
• 49 Qiu Q, Xing L, Wang Y, Feng A, Wen Q. Development and validation of a radiomics nomogram using computed tomography for differentiating immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis for patients with non-small cell lung cancer. Front Immunol 2022; 13: 870842
• 50 Grinshpun A, Zick A, Perri T. et al. Detection of antibody-drug conjugate-induced interstitial lung disease using circulating cell-free DNA. ESMO Open 2024; 9 (10) 103715
• 51 U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). National Institutes of Health. v 5.0. 2017. Accessed August 1, 2025 at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x211.pdf
• 52 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Management of Immunotherapy-Related Toxicities V1.2025. National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 1, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org
• 53 Camus P. . Pneumotox Online: The Drug-Induced Respiratory Disease Website. 2024. Accessed March 15, 2025 at: https://www.pneumotox.com/drug/index/
• 54 Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001; 85 (09) 1247-1250
• 55 Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006; 129 (04) 1031-1038
• 56 Thomas AL, Cox G, Sharma RA. et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 2000; 36 (18) 2329-2334
• 57 Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16 (10) 3426-3432
• 58 Grande C, Villanueva MJ, Huidobro G, Casal J. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 2007; 9 (09) 578-581
• 59 Anoop TM, Joseph R, Unnikrishnan P, Thomas F, Venugopal M. Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge. Lung India 2022; 39 (02) 158-168
• 60 Singavi AK, Ramalingam V, George B. Etanercept for treatment of taxane-induced pneumonitis. J Oncol Pract 2019; 15 (10) 556-557
• 61 Umemura S, Yamane H, Suwaki T. et al. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer. J Cancer Res Clin Oncol 2011; 137 (10) 1469-1475
• 62 Arrieta O, Gallardo-Rincón D, Villarreal-Garza C. et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 2009; 4 (07) 845-852
• 63 Belknap SM, Kuzel TM, Yarnold PR. et al. Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 2006; 106 (09) 2051-2057
• 64 Ohe Y, Ichinose Y, Nakagawa K. et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008; 14 (13) 4206-4212
• 65 Eagle Pharmaceuticals. Pemfexy (pemetrexed) package insert. Woodcliff Lake, NJ: Eagle Pharmaceuticals; 2020
• 66 Hochstrasser A, Benz G, Joerger M, Templeton A, Brutsche M, Früh M. Interstitial pneumonitis after treatment with pemetrexed: a rare event?. Chemotherapy 2012; 58 (01) 84-88
• 67 Dajczman E, Srolovitz H, Kreisman H, Frank H. Fatal pulmonary toxicity following oral etoposide therapy. Lung Cancer 1995; 12 (1–2): 81-86
• 68 Gurjal A, An T, Valdivieso M, Kalemkerian GP. Etoposide-induced pulmonary toxicity. Lung Cancer 1999; 26 (02) 109-112
• 69 Wu YL, Tsuboi M, He J. et al; ADAURA Investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383 (18) 1711-1723
• 70 Cho BC, Lu S, Felip E. et al; MARIPOSA Investigators. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med 2024; 391 (16) 1486-1498
• 71 AstraZeneca Pharmaceuticals. Tagrisso (osimertinib) package insert. Wilmington, DE; AstraZeneca Pharmaceuticals 2022
• 72 Janssen Biotech. Lazcluze (lazertinib) package insert. Horsham, PA: Janssen Biotech; 2024. .
• 73 Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003; 8 (04) 303-306
• 74 Reck M, van Zandwijk N, Gridelli C. et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV tarceva lung cancer survival treatment study. J Thorac Oncol 2010; 5 (10) 1616-1622
• 75 Pfizer Labs. Vizimpro (dacomitinib) package insert. New York, NY: Pfizer Labs; 2018
• 76 Sequist LV, Yang JC, Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31 (27) 3327-3334
• 77 Janssen Biotech. Rybrevant (amivantamab) package insert. Horsham, PA: Janssen Biotech; 2021. .
• 78 Min JH, Lee HY, Lim H. et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 2011; 68 (05) 1099-1109
• 79 Nishioka N, Imai H, Endo M. et al. Real-world data on subsequent therapy for first-line osimertinib-induced pneumonitis: safety of EGFR-TKI rechallenge (Osi-risk study TORG-TG2101). Target Oncol 2024; 19 (03) 423-433
• 80 Kanaji N, Ichihara E, Tanaka T. et al. Efficacy and safety of re-administration of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after EGFR-TKI-induced interstitial lung disease (CS-lung-005). Lung 2024; 202 (01) 63-72
• 81 Taronna G, Leonetti A, Gustavo Dall'Olio F. et al. Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib. Tumori 2022; 108 (06) 592-599
• 82 Gettinger SN, Bazhenova LA, Langer CJ. et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 2016; 17 (12) 1683-1696
• 83 Qie W, Zhao Q, Yang L. et al. Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: an updated systematic review and meta-analysis. Cancer Med 2023; 12 (13) 13873-13884
• 84 Créquit P, Wislez M, Fleury Feith J. et al. Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review. J Thorac Oncol 2015; 10 (08) 1148-1155
• 85 Hwang HJ, Kim MY, Choi CM, Lee JC. Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: clinical and radiologic characteristics and risk factors. Medicine (Baltimore) 2019; 98 (48) e18131
• 86 Lin L, Zhao J, Kong N. et al. Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. Oncotarget 2017; 8 (34) 57379-57385
• 87 Takeda Pharmaceutical Company Limitied. Alunbrig (brigatinib) package insert. Cambridge, MA: Takeda Pharmaceutical Company; 2020
• 88 Huang JR, Chou CW, Chao HS. Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease. J Oncol Pharm Pract 2021; 27 (05) 1311-1314
• 89 Monzonís X, Arriola E. Early onset pulmonary toxicity with lorlatinib in a patient with previous pulmonary toxicity from brigatinib. J Thorac Oncol 2019; 14 (11) e247-e248
• 90 Planchard D, Sanborn RE, Negrao MV, Vaishnavi A, Smit EF. BRAF^V600E-mutant metastatic NSCLC: disease overview and treatment landscape. NPJ Precis Oncol 2024; 8 (01) 90
• 91 Chalmers A, Cannon L, Akerley W. Adverse event management in patients with BRAF V600E-mutant non-small cell lung cancer treated with dabrafenib plus trametinib. Oncologist 2019; 24 (07) 963-972
• 92 Schmitt L, Schumann T, Löser C, Dippel E. Vemurafenib-induced pulmonary injury. Onkologie 2013; 36 (11) 685-686
• 93 Lu K, Tse V, Altaie G, Husain H. Efficacy and tolerability of osimertinib with dabrafenib and trametinib in BRAF V600E acquired EGFR-mutant non-small cell lung cancer: a case series. J Thorac Dis 2024; 16 (08) 5379-5387
• 94 Jänne PA, Riely GJ, Gadgeel SM. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS^G12C mutation. N Engl J Med 2022; 387 (02) 120-131
• 95 Skoulidis F, Li BT, Dy GK. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021; 384 (25) 2371-2381
• 96 Nakajima EC, Drezner N, Li X. et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin Cancer Res 2022; 28 (08) 1482-1486
• 97 Mirati Theruapeutics. Krazati (adagrasib) package insert. San Diego, CA: Mirati Therapeutics; 2024
• 98 Mathieu LN, Larkins E, Akinboro O. et al. FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations. Clin Cancer Res 2022; 28 (02) 249-254
• 99 Wolf J, Seto T, Han JY. et al; GEOMETRY mono-1 Investigators. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 2020; 383 (10) 944-957
• 100 Hashiguchi MH, Sato T, Yamamoto H. et al. Successful tepotinib challenge after capmatinib-induced interstitial lung disease in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation: case report. JTO Clin Res Rep 2021; 3 (02) 100271
• 101 Kim J, Bradford D, Larkins E. et al. FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin Cancer Res 2021; 27 (20) 5452-5456
• 102 Lilly USA. Retevmo (selpercatinib) package insert. Indianapolis, IN: Lilly USA; 2022.
• 103 Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X. Antibody-drug conjugates in lung cancer: dawn of a new era?. NPJ Precis Oncol 2023; 7 (01) 5
• 104 Ahn MJ, Tanaka K, Paz-Ares L. et al; TROPION-Lung01 Trial Investigators. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III tropion-lung01 study. J Clin Oncol 2025; 43 (03) 260-272
• 105 Camidge DR, Bar J, Horinouchi H. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II luminosity trial. J Clin Oncol 2024; 42 (25) 3000-3011
• 106 Modi S, Saura C, Yamashita T. et al; DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020; 382 (07) 610-621
• 107 Li BT, Smit EF, Goto Y. et al; DESTINY-Lung01 Trial Investigators. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022; 386 (03) 241-251
• 108 Goto K, Goto Y, Kubo T. et al. Trastuzumab deruxtecan in patients with her2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-lung02 trial. J Clin Oncol 2023; 41 (31) 4852-4863
• 109 Mehta GU, Vellanki PJ, Ren Y. et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. Oncologist 2024; 29 (08) 667-671
• 110 Genentech. Kadcyla (trastuzumab emtansine) package insert. South San Francisco, CA: Genentech; 2022
• 111 Nishino M, Kusumoto M, Bankier AA. et al. Trastuzumab deruxtecan-related interstitial lung disease/pneumonitis: computed tomography imaging patterns to guide diagnosis and management. JCO Precis Oncol 2023; 7: e2300391
• 112 Baba T, Kusumoto M, Kato T. et al. Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan. Int J Clin Oncol 2023; 28 (12) 1585-1596
• 113 Cadranel J, Canellas A, Matton L. et al. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. Eur Respir Rev 2019; 28 (153) 190058
• 114 Reuss JE, Suresh K, Naidoo J. Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond. Curr Oncol Rep 2020; 22 (06) 56
• 115 Naidoo J, Wang X, Woo KM. et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017; 35 (07) 709-717
• 116 Zhang Q, Tang L, Zhou Y, He W, Li W. Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management. Front Immunol 2021; 12: 663986
• 117 Rizvi NA, Hellmann MD, Brahmer JR. et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016; 34 (25) 2969-2979
• 118 Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2016; 2 (10) 1346-1353
• 119 Schneider BJ, Naidoo J, Santomasso BD. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021; 39 (36) 4073-4126
• 120 Daetwyler E, Wallrabenstein T, König D. et al. Corticosteroid-resistant immune-related adverse events: a systematic review. J Immunother Cancer 2024; 12 (01) e007409
• 121 Beattie J, Rizvi H, Fuentes P. et al. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer 2021; 9 (02) e001884
• 122 Luo J, Beattie JA, Fuentes P. et al. Beyond steroids: immunosuppressants in steroid-refractory or resistant immune-related adverse events. J Thorac Oncol 2021; 16 (10) 1759-1764
• 123 Balaji A, Hsu M, Lin CT. et al. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer 2021; 9 (01) e001731
• 124 Moodabagil M, Easterling R, Peng J. et al. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis. Oncologist 2024; 29 (11) e1575-e1585
• 125 Stroud CR, Hegde A, Cherry C. et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 2019; 25 (03) 551-557
• 126 Khanna D, Denton CP, Jahreis A. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387 (10038): 2630-2640
• 127 Camard M, Besse B, Cariou PL. et al. Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. Respir Med Res 2022; 82: 100969
• 128 Pan L, Meng F, Wang W. et al. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: a case report and literature review. Front Immunol 2023; 13: 1072612
• 129 Ogusu S, Harutani Y, Tozuka T. et al. Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer. Cancer Immunol Immunother 2023; 72 (11) 3765-3772
• 130 Li Y, Jia X, Zhang Y. et al. Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis. J Immunother Cancer 2023; 11 (06) e006982
• 131 Suresh K, Naidoo J, Zhong Q. et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Invest 2019; 129 (10) 4305-4315